Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.5K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

1.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
1.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

465
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
465
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

646
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
646
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

552
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
552
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.2K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short-term and mid-term blood pressure variability in acute myocardial infarction: a prospective cohort study on in-hospital and long-term prognostic impact.

Journal of hypertension·2026
Same author

The Role of miRNAs in Chemotherapy-Induced Cardiotoxicity.

Biomedicines·2025
Same author

Vitamin K-Dependent Inhibition Mechanisms in Human Aortic Valve Calcification.

Maedica·2025
Same author

Prediction of All-Cause Mortality and Cardiovascular Outcomes Using Ambulatory Arterial Stiffness and Ankle-Brachial Indices in Patients with Acute Myocardial Infarction: A Prospective Cohort Study.

Journal of clinical medicine·2025
Same author

The Effect of Renal Denervation on Capillary Density in Patients With Uncontrolled Hypertension.

Microcirculation (New York, N.Y. : 1994)·2025
Same author

Atrial Fibrillation Recurrence After Catheter Ablation: The Puzzle We Have and the Pieces We Need.

Pacing and clinical electrophysiology : PACE·2025

Related Experiment Video

Updated: Feb 20, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

Statins and vulnerable plaque.

Maria Drakopoulou1, Konstantinos Toutouzas1, Archontoula Michelongona1

  • 1First Department of Cardiology, Medical School of Athens University, Hippokration Hospital, Athens. Greece.

Current Pharmaceutical Design
|October 26, 2017
PubMed
Summary

Statins help stabilize vulnerable plaques, reducing cardiovascular events. Their pleiotropic effects improve endothelial function and decrease inflammation, but further clinical trials are needed.

Keywords:
Atherosclerosisimaging modalitiesstatinvulnerable plaque

More Related Videos

Implantation of a Carotid Cuff for Triggering Shear-stress Induced Atherosclerosis in Mice
07:51

Implantation of a Carotid Cuff for Triggering Shear-stress Induced Atherosclerosis in Mice

Published on: January 13, 2012

21.1K

Related Experiment Videos

Last Updated: Feb 20, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K
Implantation of a Carotid Cuff for Triggering Shear-stress Induced Atherosclerosis in Mice
07:51

Implantation of a Carotid Cuff for Triggering Shear-stress Induced Atherosclerosis in Mice

Published on: January 13, 2012

21.1K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Inflammation Biology

Background:

  • Atherosclerosis is a progressive, lipid-driven inflammatory disease characterized by plaque development.
  • Vulnerable plaques, associated with cardiovascular events, have a lipid-rich core and thin fibrous cap.
  • Statins are primary drugs for cardiovascular disease prevention, known for vulnerable plaque stabilization.

Purpose of the Study:

  • To evaluate the beneficial effects of statins on biological processes in vulnerable plaque evolution.
  • To systematically review existing literature on statin use in vulnerable plaque.

Main Methods:

  • Systematic literature review using MEDLINE via PubMed.
  • Inclusion of experimental and human studies on statins in vulnerable plaque.

Main Results:

  • Statins demonstrate a beneficial role in plaque stabilization and patient outcomes.
  • Statin therapy improves endothelial function, reduces oxidative stress and inflammation, and inhibits thrombogenic response.
  • The full clinical benefit of statins' pleiotropic effects requires further determination.

Conclusions:

  • Further prospective randomized trials are necessary to fully understand statin therapy's impact.
  • Investigating differences in statin type, dose, and duration is crucial.
  • The association between statin therapy, LDL levels, and clinical outcomes needs further elucidation.